RFL News and Press, Rafael Holdings Inc. Class B From 10/08/19

Cranbury NJ, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, congratulates Gregg L. Semenza, M.D., Ph.D., scientific advisory board member at Raf...

Cranbury, NJ, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has enrolled 100 patients in its pivotal Phase 3 clinical tr...

Rafael Holdings (NYSEMKT: RFL ): Q4 GAAP EPS of -$0.16. Revenue of $1.4M Press Release More news on: Rafael Holdings, Inc., Earnings news and commentary, Healthcare stocks news,

NEWARK, N.J. , Oct. 3, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $4.9 million and a loss per share of $0.35 for the fiscal year ended July 31, 2019 . Fourth quarter revenue was $1.4 million and the loss per share was $0.16 . ...

Newark, NJ, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Wendy McDermott as Chief People Officer. McDermott...

CRANBURY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the Phase 3 clinical trial ( ARMADA 2000 ) of CPI-613® ...

CRANBURY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 3 clinical trial for patients with met...

Cranbury, NJ, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that peer-reviewed medical journal Future Oncology published two m...

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers’ 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers’ regulatory 13F Form filed on 08/05/2019. Please visit our Tracking Kahn Brothers Portfolio series t...

Jerusalem, Aug. 05, 2019 (GLOBE NEWSWIRE) --   LipoMedix Pharmaceuticals Ltd. , a clinical and development-stage company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery, today announced the addition of  Miranda J. Toledan...